Although AKR1B10 is downregulated in gastrointestinal cancers and inflammatory bowel diseases [19,20], it is later found to be differentially upregulated and proposed as a prognostic biomarker in numbers of other cancer types, such as nasopharyngeal carcinoma, breast, pancreatic, and lung cancers [21,22,23]. Here, AKR1B10 is linked to lung carcinoma.